Drug Profile
Monoclonal antibody Hu8H9 I-131 - Y-mAbs Therapeutics
Alternative Names: 131I-Hu8H9 (B7-H3)Latest Information Update: 22 Sep 2023
Price :
$50
*
At a glance
- Originator Memorial Sloan-Kettering Cancer Center
- Developer Y-mAbs Therapeutics
- Class Monoclonal antibodies; Radiopharmaceuticals
- Mechanism of Action Antibody-dependent cell cytotoxicity; CD antigen modulators; Immunostimulants; Ionising radiation emitters
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Soft tissue sarcoma
Most Recent Events
- 22 Sep 2023 Discontinued - Preclinical for Soft tissue sarcoma in USA (Parenteral)
- 28 Nov 2020 No recent reports of development identified for preclinical development in Soft tissue sarcoma in USA (Parenteral)
- 04 Oct 2016 Preclinical trials in Soft tissue sarcoma in USA (Parenteral)